News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II (World)
National Center for Child Health And Development Initiates Phase 1/2 Trial Of Green Cross' Idursulfase-Beta ICV For The Treatment Of Hunter Syndrome With Neurocognitive Decline 10/26/2016
Debiopharm Reaches Important Development Milestones For Its Staphylococcus-Selective Antibiotic Debio 1450 10/25/2016
Roche (RHHBY)'s Avastin Successor Flunks Key Study, Turns Hope to Tecentriq Instead 10/21/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Meets Primary And Secondary End Points In Metabolic Syndrome And Type 2 Diabetes Phase 2 Clinical Trial 10/20/2016
Sanifit Announces Initiation Of First Clinical Trial Of SNF472 In Patients With Calciphylaxis 10/20/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
FDA Slaps Hold on Regeneron (REGN), Teva (TEVA)'s Pain Drug Fasinumab 10/18/2016
Addex Therapeutics (ADXN.SW) To Conduct Phase IIa Proof Of Concept Study Of Dipraglurant In Focal Cervical Dystonia 10/17/2016
MorphoSys AG Presents Updated Clinical Results For MOR202 At Medical Conference 10/17/2016
Hua Medicine's GKA Diabetes Treatment Passes Proof-of-Concept Trial 10/17/2016
NeuroVive (NVP) Stock Craters After Discontinuing Acute Kidney Injury Program 10/13/2016
BIOCAD Biotechnology Company Announces The Start Of Phase 2 Clinical Trials Of An Innovative Drug To Treat Severe Psoriasis 10/13/2016
Synairgen (SNG.L) Stock Tanks After Partner AstraZeneca PLC (AZN) Halts Asthma Drug Trial 10/12/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Significantly Reduces Liver Fibrosis In Patients With Alström Syndrome 10/12/2016
PharmaMar Announces Positive Results From Its Phase II Study With Lurbinectedin In BRCA 1/2 - Associated Metastatic Breast Cancer At The ESMO 2016 Congress 10/10/2016
Karolinska Development AB Portfolio Company Aprea Enrolls First Patients In Phase II Trial Of APR-246 In Ovarian Cancer 10/10/2016
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 2 Combination Trial Of PROSTVAC And Ipilimumab In Patients With Localized Prostate Cancer 10/10/2016
Bone Therapeutics Reports Positive Efficacy Data For The ALLOB Phase IIA Spinal Fusion Trial 10/5/2016
Theranexus Has Obtained An Orphan Drug Designation From The FDA For THN102 In The Treatment Of Narcolepsy 10/4/2016
TheraVida, Inc. Release: THVD-102 Demonstrates Promising Potential As An Orally Administered Treatment For Hyperhidrosis 10/3/2016
Quantum Genomics Corp. Reports Positive Top-Line Results From Phase IIa Trial Of QGC001 In Hypertension 9/30/2016
Neurim Pharmaceuticals Announces First Patients' Enrollments In ReCOGNITION - Phase II Clinical Trial Of Piromelatine For Mild Alzheimer's Disease 9/28/2016
Ipsen (IPN.PA) Announces Data Presentations Of Cabozantinib (Cabometyx), Lanreotide (Somatuline® Autogel®) And Telotristat Ethyl* At The European Society For Medical Oncology (ESMO) 2016 Congress 9/27/2016
Galapagos (GLPG.BR) Release: Endoscopic Improvements With Filgotinib Are Consistent With Clinical Remission Rates In Patients With Crohn's Disease 9/26/2016
Medivir (MVRBF): Updated Interim Phase IIa Data Demonstrate That The Combination Of Simeprevir, Odalasvir And AL-335 Has A High Level Of Efficacy In HCV Patients 9/26/2016
Medivir (MVRBF): MIV-711 Osteoarthritis Trial: Recommendation To Go Ahead Based On Independent Review Of Safety Data, And First Patient Enrolled In Extension Study 9/23/2016
Nordic Nanovector: Safety Review Committee Supports Dose Escalation With Betalutin In Lymrit 37-01 Trial Pending Safety Data From Cohort Receiving Higher Pre-Dosing 9/23/2016
Fundación MAPFRE Presents The Results Of Personalized Cell Therapy For Treating Spinal Cord Injury 9/23/2016
ASIT Biotech Announces The Initiation Of A Phase IIa Clinical Study Of Its Second Product Candidate Hdm-ASIT+TM For House Dust Mite Rhinitis 9/22/2016
Bionomics Limited (BNO.AX) Announces Positive Results From Phase 2 Trial Of BNC210 In Generalized Anxiety Disorder 9/21/2016
DBV Tech Receives FDA Fast Track Designation For Viaskin Milk For The Treatment Of Cow’s Milk Protein Allergy 9/21/2016
BiondVax Pharmaceuticals Phase 2b European Trial: Last Patient Out 9/21/2016
BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 9/20/2016
NeuroDerm (NDRM) To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System 9/19/2016
Astellas (ALPMY), Vical  (VICL)'s Experimental Herpes Vaccine Flunks Mid-Stage Test 9/19/2016
Teva (TEVA) Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study Of Pridopidine In Huntington Disease 9/19/2016
Celgene (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase 2 Radiance Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
Celgene International Sárl (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase II RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
Eisai Company (ESALY.PK) Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 9/15/2016
Poxel SAS Presents New Data On Imeglimin And PXL770 At The European Association For The Study Of Diabetes Annual Meeting 9/15/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease 9/15/2016
Euroscreen S.A. Completes Enrollment In Phase II Trial Of Lead Candidate ESN364 In Menopausal Hot Flashes 9/14/2016
Foamix Pharma (FOMX) To Announce Topline Results In Phase 2 Clinical Trial Of FMX-103 Minocycline Topical Foam For Moderate-To-Severe Papulopustular Rosacea 9/9/2016
Medivir (MVRBF): Interim Results From Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level Of Efficacy In HCV Patients 9/9/2016
ErgoMed Completes Recruitment Of Phase lla Clinical Trial Of Lorediplon In Insomnia In Collaboration With Co-Development Partner Ferrer 9/8/2016
BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference 9/8/2016
RedHill Biopharma (RDHL) Announces Phase Ib/II Study With YELIVA Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center 9/8/2016
Cancer Drug Developed by Eliza Hall Institute, AbbVie (ABBV) and Genentech (RHHBY) “Melts Away Cancer” 9/7/2016
Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99mrhannexin V-128 Imaging In Cardiovascular And Cardio-Oncology Indications At University of Ottawa Heart Institute And Ottawa Hospital 9/6/2016
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016
Galapagos (GLPG.BR) Release: Orphan Drug Designation In European Union For GLPG1690 In Idiopathic Pulmonary Fibrosis 9/6/2016
Nordic Nanovector: Lilotomab Pre-Dosing Of NHL Patients Before Betalutin Therapy Lowers Hematological Toxicity With No Reduction In The Tumor Absorbed Radiation Dose 9/6/2016
Sensorion Obtains FDA Approval To Initiate A Clinical Study Of SENS-111 In Acute Severe Vertigo 9/1/2016
Heart Metabolics Limited Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy 8/31/2016
Primex Pharma: Next Real Innovation In Paediatric Anaesthesia Since Propofol 8/31/2016
Kamada Ltd. (KMDA) Meets Primary Endpoint Of U.S. Phase II Study Of Inhaled Alpha-1 Antitrypsin For The Treatment Of Alpha-1 Antitrypsin Deficiency 8/30/2016
Betagenon AB: Start Of Phase IIa Proof-Of-Concept Clinical Trial Of AMPK Activator O304 In Type 2 Diabetics 8/30/2016
Bone Therapeutics Announces H1 Results For 2016 8/30/2016
Shionogi Presents Results From A Phase 2 Proof-Of-Concept Clinical Trial And Non-Clinical Studies Of S-033188, A Novel Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza 8/29/2016
Exalenz Bioscience Announces Collaboration With Conatus Pharma To Use BreathID To Monitor Patients With Cirrhosis Associated With NASH 8/29/2016
Seqirus Presents Analysis Reinforcing The Safety And Immunogenicity Profiles Of Its MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine In Adults 65 Years And Older 8/29/2016
Themis: Phase 2 Trial Of Leading Chikungunya Vaccine Candidate Started 8/25/2016
Nordic Nanovector Completes Recruitment Of The First Cohorts Of Arm 3 And Arm 4 Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients 8/18/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
Three CardioCell-Sponsored Studies Reveal Results At The European Society of Cardiology Congress 2016 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
MMJ PhytoTech Ltd To Commence Phase 2 Clinical Trial On Pediatric Epilepsy 8/15/2016
Medivir (MVRBF): New Interim Phase IIa Data On Simeprevir In Combination With Other Daas Will Be Presented At The Upcoming EASL AASLD Special Conference 8/11/2016
Oncolytics Biotech Inc. (ONC.TO) Reports Additional Data From Randomized Phase II Study Of REOLYSIN In Non-Small Cell Lung Cancer 8/10/2016
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA For Pancreatic Cancer 8/8/2016
Can-Fite BioPharma (CFBI)'s Phase II/III Psoriasis Study Results Published In Journal Of Drugs In Dermatology 8/8/2016
MorphoSys AG Successfully Completes Safety Run-in Of MOR208 In L-MIND Combination Study In Patients With DLBCL 8/3/2016
VM BioPharma Announces Korea Food And Drug Administration Approval Of Phase 2 Clinical Trial For Investigational Gene Therapy VM202 In Ischemic Heart Disease 8/2/2016
Angle: Use Of Parsortix In GANNET53 Drug Trial 8/1/2016
Biophytis Receives Approval Of Bpifrance For An Innovation Loan Of €1.1 Million To Finance The SARA-PK Trial 7/29/2016
Oramed (ORMP) Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering Of Glucose Levels Vs Placebo 7/28/2016
Chugai Pharma's Emicizumab Showed Continued Benefits In Patients With Hemophilia A 7/28/2016
vTv Therapeutics Announces Presentation Of Phase 2b Azeliragon Results At The 2016 Alzheimer’s Association International Conference (AAIC) 7/28/2016
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016
Poxel Announces Publication Of Important New Mechanism Data For Imeglimin Relating To Insulin Secretion In The Treatment Of Type 2 Diabetes 7/26/2016
BioInvent (BOVNF) Interim Report 1 January – 30 June 2016 7/26/2016
Cell Medica Release: Lead Cancer Immunotherapy Candidate Granted EU Orphan Drug Designations 7/20/2016
Akari Therapeutics Receives Approval From The UK Medicines & Healthcare Products Regulatory Agency To Conduct Phase II Trial In Paroxysmal Nocturnal Hemoglobinuria 7/13/2016
AbbVie (ABBV)'s $175 Million Gamble Pays Off as Ablynx (ABLYF) RA Drug Meets Goal in Phase II Study 7/8/2016
OphthaliX Inc. Announces Phase II Glaucoma Data 7/5/2016
NeuroDerm (NDRM) Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 7/1/2016
Poxel SAS Announces Patient Enrollment Completed For Imeglimin Phase 2b Clinical Trial In Type 2 Diabetes In Japan 6/30/2016
Aurinia (ISA.TO) Announces 24 Week Remission Rates From The First Seven Patients In Its Open Label AURION Study In Lupus Nephritis (LN) 6/29/2016
BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 6/28/2016
Mologen (MOLGF.PK): First Patients Enrolled In Extension Phase Of The HIV Study TEACH 6/28/2016
Allergy Therapeutics Phase II Fails to Find Hay Fever Therapy Dose Range 6/27/2016
TWi Biotechnology Announces Last Patient Enrolled In Phase 2 Study Of AC-201CR For Gout Treatment 6/27/2016
Wilson Therapeutics Presents Preliminary Clinical Data On Decuprate At The 20th International Congress Of Parkinson´s Disease And Movement Disorders 6/23/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Frontier Biotechnologies Reports Primary Endpoint Met In Phase 2 Trial Of AB001 In Chronic Low Back Pain 6/22/2016
Ascletis, Inc. Publishes Interim Data Of Phase II Study In Taiwan For Its Interferon-Free HCV Regimen 6/21/2016
Oramed (ORMP) Announces $6.5 Million Milestone Payment From HTIT 6/21/2016
Takeda (TKPYY) Initiates World’s First Norovirus Vaccine Field Trial 6/20/2016
NLS Pharma Release: FDA Accepts IND For Phase II Study Of Mazindol In Adults With ADHD 6/16/2016
Hansa Medical: Successful Desensitization With IdeS In All Recruited Patients In Ongoing U.S. Phase II Study 6/15/2016
Agios (AGIO)' Anemia Drug Data Hits Mark in Mid-Stage Study 6/13/2016
Sophiris Bio (SPHS) Reports Successful Results From Completed Phase 2a Study Of Topsalysin In Localized Prostate Cancer 6/10/2016
Galmed Pharmaceuticals Adds China Arm To Phase IIb Trial Of Liver Disease Drug 6/9/2016
Paradigm Provides Clinical Trial Update 6/9/2016
Istituto Superiore di Sanita Release: Improving The Effect Of HIV Drugs By Use Of The Tat Vaccine 6/8/2016
Bone Therapeutics Demonstrates Superiority Of PREOB In Phase IIB Osteonecrosis Study Presented At EULAR 6/8/2016
Galmed Pharmaceuticals Expands Its Ongoing Phase IIb ARREST Study To China 6/7/2016
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1143 In Ovarian Cancer 6/7/2016
NeuroVive (NVP) Announces CiPRICS Study Completes Enrollment 6/7/2016
ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016 6/6/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: OBI Pharma (SHPG) Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: New Data On Olmutinib (BI 1482694) Presented At ASCO 2016 Underscores Clinical Potential Of Boehringer Ingelheim’s Next Generation Lung Cancer Compound 6/6/2016
ASCO2016: MorphoSys AG Presents Updated Clinical Data For MOR202 In Multiple Myeloma And For MOR208 In Non-Hodgkin's Lymphoma At ASCO 2016 6/6/2016
ASCO2016: CellAct Pharma Phase II CAP7.1 Population Pharmacokinetic Data Supports Efficacy Results In Biliary Tract Cancers 6/3/2016
Isofol Medical AB Has Successfully Advanced To The Next Dose Level Of Modufolin In A Phase I/II Clinical Trial In Colorectal Cancer 6/2/2016
Addex Therapeutics (ADXN.SW) Dipraglurant Positive Phase 2 Data In PD-LID Published In Leading Peer Reviewed Journal Of The Movement Disorder Society 6/2/2016
Boehringer Ingelheim Launches Ambitious ELUXA Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016
PharmaEngine, Inc. Announces Initiation Of Global Pivotal Trial Of PEP503 (NBTXR3) In Soft Tissue Sarcoma In Asia Pacific Region 6/1/2016
ProNAi Therapeutics, Inc. Appoints Dr. Christian Hassig As Senior Vice President Of Research 6/1/2016
Hansa Medical: Initial Results From The Ongoing Swedish Phase II Study With Ides In Sensitized Kidney Transplant Patients Will Be Presented At TTS 2016 5/31/2016
GeNeuro Announces First Patients Treated In Phase IIb Study For Multiple Sclerosis 5/31/2016
Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology 5/31/2016
Ongoing Clinical Development Of ABX464: ABIVAX Launches ABX464-004 Study 5/31/2016
Antibe Therapeutics (ATE.V) Presenting Update On ATB-346 At International Hydrogen Sulfide Conference 5/31/2016
Can-Fite BioPharma (CFBI) Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update 5/27/2016
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection 5/25/2016
TxCell Obtains Authorization From European Regulatory Authorities To Restart Ovasave Phase IIb Clinical Trial 5/25/2016
Boehringer Ingelheim Release: IL-23 Inhibitor Risankizumab Induces Remission In Phase II Study In Patients With Moderate-To-Severe Crohn’s Disease 5/24/2016
Isofol Medical AB Announces Successful Meetings With European And US Regulatory Authorities Regarding The Design Of A Pivotal Phase II Clinical Trial Of Isofol's Lead Drug Candidate, Modufolin 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
DS Biopharma Announces DS102 Will Be Developed For Pulmonary Disorders In Addition To NASH 5/23/2016
ViroMed Of Korea Receives U.S. Fast Track Status For Gene Therapy 5/20/2016
NovoCure Enrolls Last Patient In INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel In Recurrent Ovarian Cancer 5/20/2016
ProNAi Therapeutics, Inc. To Report Wolverine Phase 2 Interim Results On June 6th At ASCO 5/19/2016
Bone Therapeutics To Enhance Value Of Its Severe Osteoporosis Program By Transitioning To Allogeneic Development 5/19/2016
BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences 5/19/2016
NovoCure Announces Presentation Of Subgroup Analysis Of PANOVA Data Showing Overall Survival Benefit Of Tumor Treating Fields Plus Gemcitabine In Advanced Pancreatic Cancer Patients 5/19/2016
Oncolytics Biotech Inc. (ONC.TO) Reports Preliminary Data From Randomized Phase II Study Of REOLYSIN In Non-Small Cell Lung Cancer 5/19/2016
Health Canada Authorizes ProMetic Life Sci (PFSCF.PK) To Proceed With Its PBI-4050 Clinical Trial In Patients With Cystic Fibrosis 5/18/2016
Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled 5/18/2016
Sophiris Bio (SPHS) Reports First Quarter 2016 Financial Results And Key Business Highlights 5/17/2016
BioLineRx Reports First Quarter 2016 Financial Results 5/17/2016
Bone Therapeutics Announces Further Positive Efficacy In ALLOB Phase I/IIA Delayed-Union Fracture Trial 5/17/2016
Theranexus Reaches Its Primary Endpoint In The Proof Of Concept Trial Of THN102 In Excessive Daytime Sleepiness (EDS) 5/17/2016
Hansa Medical: Ongoing US Study Shows That IdeS Allows For Transplantation Of Highly Sensitized Patients 5/17/2016
Allergan (AGN) Shows Off Positive Mid-Stage Data for Oculeve Intranasal Tear Neurostimulator 5/16/2016
BioSight Release: Arkin Holdings And Primera Capital Lead An Investment Of $13M In Biosight For An Innovative Treatment Of Acute Leukemia 5/16/2016
BioLineRx And MaRS Innovation Sign Framework Collaboration Agreement 5/16/2016
Mundipharma And Purdue Pharma L.P. Expand Pain Pipeline With New Deal For First-In-Class Sigma-1 Antagonist (S1A Or MR309/E-52862) From ESTEVE 5/16/2016
BioNevia And Neuromax Announce Completion Of Enrollment In Phase IIb Clinical Trial Of BNV-222 5/16/2016
PledPharma Release: New Data Strengthens Claim That Pledox Does Not Negatively Interfere With The Anti-Cancer Effect Of Chemotherapy 5/16/2016
Transition Therapeutics (TTH.TO) Announces Third Quarter Fiscal 2016 Financial Results 5/12/2016
Helix Release: First Patient Dosed In Phase II Study Of L-DOS47 In Non-Small Cell Lung Cancer 5/12/2016
Braeburn Pharma, Camurus Announce Positive Mid-Stage CAM2038 Data in Patients With Opioid Use Disorder 5/11/2016
Medivir (MVRBF) Announces That Janssen R&D Decided To Start A Phase IIb Study Of Combinations Of Simeprevir, Odalasvir And AL-335 For The Treatment Of Hepatitis C 5/11/2016
ProNAi Therapeutics, Inc. Reports First Quarter 2016 Results 5/10/2016
BrainStorm Cell Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/10/2016
BioLineRx To Report First Quarter 2016 Results On May 17, 2016 5/10/2016
Verona Pharma (VRP.L) Announces Positive Results From "Add-On" Phase II Trial With RPL554 5/10/2016
Allergy Therapeutics plc Race with Positive Phase II Data for Hayfever 5/9/2016
Galmed Pharmaceuticals First Quarter 2016 Conference Call And Webcast Scheduled For Monday, May 16th, 2016 5/9/2016
Aurinia (ISA.TO) Initiates First Clinical Study Of Voclosporin For Japan 5/9/2016
NeuroDerm (NDRM) Announces Patient Enrollment In Long-Term Safety Trial Of ND0612 For Parkinson’s Disease 5/9/2016
Oncolytics Biotech Inc. (ONC.TO) Announces 2016 First Quarter Results 5/6/2016
Novaliq GmbH Announces Last Patient Enrolled In Phase II Clinical Trial Of Cyclasol For The Treatment Of Moderate To Severe Dry Eye Disease 5/5/2016
Opthea Doses First Patient In Phase 2A Dose Expansion Study For OPT-302 In Wet AMD 5/5/2016
SELLAS Life Sciences Group Announces Positive WT1 Cancer Vaccine (Galinpepimut-S) Clinical Results At The 13th International Conference Of The International Mesothelioma Interest Group (iMig) 5/4/2016
ProMetic Life Sci (PFSCF.PK) Announces Successful Treatment Of A Plasminogen-Deficient Patient Under An Expanded Access (Compassionate Use) Protocol In The USA 5/3/2016
Mount Sinai And Galmed Pharmaceuticals To Collaborate In An Investigator Initiated Phase Ila Trial To Evaluate The Effect Of AramcholTM In Combination With Vitamin D For The Treatment Of Patients With Fibrotic Nonalcoholic Fatty Liver Disease 5/3/2016
Foamix Pharma (FOMX) Announces Completion Of Enrollment In Phase II Clinical Trial Of Minocycline Foam (FMX103) For Treatment Of Papulopustular Rosacea 5/3/2016
Bone Therapeutics Completes Recruitment Of Its ALLOB Phase IIA Spinal Fusion Study 5/3/2016
Ablynx (ABLYF) Reports Positive Top Line Results For Its Anti-RSV Nanobody (ALX-0171) Inhaled Using Vectura (VEC.L)’s FOX Device In A Phase I/IIa Study In Infants Hospitalized With RSV Infection 5/3/2016
Can-Fite BioPharma (CFBI) To Present Data On Cf602 In The Treatment Of Erectile Dysfunction At American Urological Association's Annual Meeting 5/2/2016
BioInvent (BOVNF), Oncurious And NMTRC Initiating Phase I/IIa Study With TB-403 For The Treatment Of Medulloblastoma 5/2/2016
Glycotope Appoints Dr. Alfredo Zurlo As Chief Medical Officer 4/29/2016
Can-Fite BioPharma (CFBI) To Present At Joseph Gunnar & Co.'s Pioneers 2016 Conference In New York City On May 5, 2016 4/29/2016
Neovacs Obtains FDA Approval To Extend Its Phase IIb Clinical Trial In Lupus To United States 4/29/2016
Anavex (AVXL)’s Alzheimer’s Drug a Possible Game Changer After Patients Reported Remarkable Positive Response 4/28/2016
Neovacs Obtains FDA Approval To Extend Its Phase IIb Clinical Trial In Lupus To United States 4/28/2016
Life Science Startup Company Strekin AG Announces The Launch Of A Phase 2 Clinical Study Of STR001 As A Potential New Treatment For Hearing Loss 4/27/2016
ABIVAX Abstract On ABX464 Selected For Presentation At The AIDS 2016 Conference In Durban, South Africa 4/27/2016
Transition Therapeutics (TTH.TO) Announces Dosing Of First Patient In Phase 2 Study Of Drug Candidate TT701 4/26/2016
Novartis AG (NVS)'s Breakthrough Muscle Drug Fails to Meet Primary Goal in Patients with sIBM 4/21/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/20/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/19/2016
AbbVie (ABBV)'s New Hep C Regimen Shows High Cure Rates in Mid-Stage Trial 4/18/2016
MorphoSys AG Licensing Partner GlaxoSmithKline (GSK) Starts Phase 2 Study With GSK3196165 (MOR103) In Hand Osteoarthritis 4/18/2016
Pharma Mar Will Be Present At The 2016 Annual AACR Congress With The Latest Novelties In Its Compounds Of Marine Origin In Solid And Hematological Tumors 4/14/2016
Bay Area's Tobira Strikes a $74.5 Million Evogliptin and Cenicriviroc Deal with Dong-A ST 4/11/2016
Medivir (MVRBF): New Data For Simeprevir Will Be Presented At Easl's International Liver Congress 2016 4/11/2016
ORYZON Genomics Release: Data On ORY-1001 To Be Presented At The AACR Annual Meeting 2016 In New Orleans 4/11/2016
Debiopharm To Present The Latest Findings On Debio 1450 At ECCMID 4/8/2016
Galapagos (GLPG.BR) Initiates A Phase IIa Study With GLPG1690 In Idiopathic Pulmonary Fibrosis Patients 4/7/2016
Portage Biotech Announcing Results Of Its Annual Shareholder Meeting And Other Corporate Matters 4/7/2016
SanBio, Inc. Release: Clinical Trial Involving Regenerative Cell Treatment For Patients With Traumatic Brain Injury Permitted In Japan 4/6/2016
Kamada Ltd. (KMDA) Announces Initiation Of Phase 2 Clinical Trial With Intravenous Alpha-1 Antitrypsin For The Prevention Of Lung Transplant Rejection 4/6/2016
Oramed (ORMP) Completes Phase IIb Oral Insulin Study 4/5/2016
SELLAS Life Sciences Group Receives A Favorable Opinion For European Orphan Drug Designations For WT1 Cancer Vaccine (galinpepimut-S) For The Treatment Of Acute Myeloid Leukemia And For Malignant Pleural Mesothelioma 4/5/2016
RedHill Biopharma (RDHL) Announces Interim Results From Phase IIa Proof-Of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis 4/5/2016